Isto eliminará a páxina "FDA Pauses PepGen’s DMD Drug Trial in the US". Por favor, asegúrate de que é o que queres.
The therapy was being evaluated in ascending doses in the 25-week, multinational, double-blind, placebo-controlled CONNECT2-EDO51 trial. According to a PepGen news release, the decision was tied to questions arising during the regulatory review and does not impact ongoing studies outside the US, such as the mid-stage trial in the United Kingdom and the open-label CONNECT1-EDO51 trial enrolling in Canada. PepGen expected to open the phase 2 CONNECT2-EDO51 trial in the US by end of year. PepGen did not mention a specific reason for the decision
Isto eliminará a páxina "FDA Pauses PepGen’s DMD Drug Trial in the US". Por favor, asegúrate de que é o que queres.